Maximilien Murone
Overview
Explore the profile of Maximilien Murone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
498
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel K, Manzo M, Hapuarachi B, Rack S, Jermann P, Feeney L, et al.
Oral Oncol
. 2023 Aug;
146:106542.
PMID: 37619521
No abstract available.
2.
Spriano F, Tarantelli C, Arribas A, Gaudio E, Cascione L, Aresu L, et al.
Br J Haematol
. 2022 Dec;
200(5):669-672.
PMID: 36484636
No abstract available.
3.
Fabbro D, Bauer M, Murone M, Lehal R
Chimia (Aarau)
. 2020 Oct;
74(10):779-783.
PMID: 33115560
Notch is a key oncogenic pathway in several human cancers and to date, no targeted treatment of Notch activated cancers is available to patients. Therapeutic targeting of Notch has been...
4.
Ferrara G, Benzi A, Sturla L, Marubbi D, Frumento D, Spinelli S, et al.
J Neuroinflammation
. 2020 Aug;
17(1):228.
PMID: 32736564
Background: Experimental autoimmune encephalomyelitis (EAE) is the most common animal model of multiple sclerosis (MS), a neuroinflammatory and demyelinating disease characterized by multifocal perivascular infiltrates of immune cells. Although EAE...
5.
Damonte P, Sociali G, Parenti M, Soncini D, Bauer I, Boero S, et al.
Bioorg Med Chem
. 2017 Sep;
25(20):5849-5858.
PMID: 28958848
The NAD-dependent deacetylase SIRT6 is an emerging cancer drug target, whose inhibition sensitizes cancer cells to chemo-radiotherapy and has pro-differentiating effects. Here we report on the identification of novel SIRT6...
6.
Murone M, Radpour R, Attinger A, Chessex A, Huguenin A, Schurch C, et al.
Mol Cancer Ther
. 2017 May;
16(8):1497-1510.
PMID: 28468777
Acute myelogenous leukemia (AML) is initiated and maintained by leukemia stem cells (LSC). LSCs are therapy-resistant, cause relapse, and represent a major obstacle for the cure of AML. Resistance to...
7.
Sociali G, Magnone M, Ravera S, Damonte P, Vigliarolo T, von Holtey M, et al.
FASEB J
. 2017 Apr;
31(7):3138-3149.
PMID: 28386046
Sirtuin 6 (SIRT6) is a sirtuin family member involved in a wide range of physiologic and disease processes, including cancer and glucose homeostasis. Based on the roles played by SIRT6...
8.
Murone M, Chessex A, Attinger A, Ramachandra R, Shetty S, Daginakatte G, et al.
Mol Cancer Ther
. 2016 Jul;
15(10):2334-2343.
PMID: 27439479
Tumor survival, metastases, chemoresistance, and escape from immune responses have been associated with inappropriate activation of STAT3 and/or STAT5 in various cancers, including solid tumors. Debio 0617B has been developed...
9.
Marshall J, Collins J, Nakayama J, Horak C, Liewehr D, Steinberg S, et al.
J Natl Cancer Inst
. 2012 Aug;
104(17):1306-19.
PMID: 22911670
Background: Previous studies identified the human nonmetastatic gene 23 (NME1, hereafter Nm23-H1) as the first metastasis suppressor gene. An inverse relationship between Nm23-H1 and expression of lysophosphatidic acid receptor 1...
10.
David M, Ribeiro J, Descotes F, Serre C, Barbier M, Murone M, et al.
Int J Oncol
. 2011 Dec;
40(4):1133-41.
PMID: 22200658
Metastasis is the main cause of death for cancer patients. Targeting factors that control metastasis formation is a major challenge for clinicians. Lysophosphatidic acid (LPA) is a bioactive phospholipid involved...